Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in Million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the pharmaceutical-related business, new drugs were the main driver of growth, while in the healthcare business, Collage Furfur and Collage Repair grew. Operating profit increased due to higher gross profit resulting from increased revenue, while ordinary profit increased due to the recognition of equity-method investment gains and other factors.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | 64,366 Million yen (YoY +17.1%) |
| Operating profit | 7,103 Million yen (YoY +43.0%) |
| Ordinary income | 8,128 Million yen (YoY +56.9%) |
| Profit attributable to owners of the parent | 6,707 Million yen (YoY +73.9%) |
| Total assets | 184,911 Million yen |
| Net assets | 142,352 Million yen |
| Cash flows from operating activities | -854 Million yen |
| Cash flows from investing activities | 836 Million yen |
| Cash flows from financing activities | -2,491 Million yen |
| Cash and cash equivalents at end of period | 28,573 Million yen |
| Revision to Earnings Forecast | No revision |
| Segment revenue | Pharmaceutical-Related Businesses 59,988 Million yen (YoY +17.5%), Healthcare business 4,378 Million yen (YoY +11.5%) |
| Depreciation and amortization | 1,881 Million yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment 2 Million yen, Gain on Sale of Investment Securities 1,032 Million yen / Extraordinary loss Loss on disposal and sale of fixed assets 3 Million yen, Costs of removing non-current assets 16 Million yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Factors Behind Changes in Business Performance | In the pharmaceutical-related business, new drugs were the main driver of growth, while in the healthcare business, Collage Furfur and Collage Repair grew. Operating profit increased due to higher gross profit resulting from increased revenue, while ordinary profit increased due to the recognition of equity-method investment gains and other factors. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceutical-related business, new drugs were the main driver of growth, while in the healthcare business, revenue from Collage Furfur and Collage Repair increased. Operating profit increased due to higher gross profit resulting from increased revenue, while ordinary profit increased due in part to the recognition of equity-method investment gains related to アンドファーマ株式会社.